Radio-guided surgery in the treatment of recurrent, initially localized prostate cancer

The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …

Abiraterone acetate vs. enzalutamide: a head-to-head study in men with CRPC

Apparently a group of Japanese researchers determined a while ago that we need to know whether abiraterone acetate (Zytiga) or enzalutamide (Xtandi) is the better drug for first-line treatment of chemotherapy-naive patients with castration-resistant prostate cancer (CRPC) — whether it is metastatic or non-metastatic in type. … READ MORE …

Does Lu-177-PSMA-617 increase survival?

We have enthusiastically reported the encouraging outcomes of the early clinical trials of the radiopharmaceutical Lu-177-PSMA, most recently at this link. Based on reduction in PSA levels, it performs well. But medicines have no real benefit if all they do is treat PSA. We want medicines that increase survival. … READ MORE …

Do men with mCRPC need to stay on ADT along with their abiraterone acetate?

On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). … READ MORE …

J&J announces positive data from the SPARTAN trial of apalutamide (ARN-509)

We understand that Janssen Biotech has, earlier today, submitted a New Drug Application to the US Food & Drug Administration for the approval of apalutamide (formerly ARN-509) in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Contemporary questions about the initial treatment of advanced forms of prostate cancer

So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …

5-year data from another large series of men on active surveillance

A new article in the Scandinavian Journal of Urology has provided 5-year outcomes data from a large, prospective, single-center study of men in Denmark initially managed on active surveillance. … READ MORE …